Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference
Cardiff Oncology (Nasdaq: CRDF) will present at Sidoti’s Year-End Virtual Investor Conference on December 11, 2025 at 4:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cardiff Oncology (Nasdaq: CRDF) will present at Sidoti’s Year-End Virtual Investor Conference on December 11, 2025 at 4:00 PM ET. CEO Mark Erlander, PhD will deliver the presentation and host one-on-one meetings during the conference running December 10–11, 2025. Interested parties can register and access the live webcast via the company’s Events section. A webcast replay will be available after the presentation.
Details
News Market Reaction – CRDF
On Dec 8, the day this news came out, CRDF closed 10.90% above the previous close.
Data tracked by StockTitan Argus for the Dec 8 session.
Key Figures
- Conference dates
- December 10–11, 2025
- Sidoti’s Year-End Virtual Investor Conference schedule
- Presentation date
- 12/11/2025
- Cardiff Oncology presentation date at Sidoti conference
- Presentation time
- 4:00 PM ET
- Scheduled time for CEO presentation
Historical Context
-
Announcement of Piper Sandler conference presentation and 1x1 investor meetings.
-
Q3 2025 results with positive Phase 2 data and extended cash runway.
-
Participation in two November 2025 investor conferences with webcasts.
-
Two October 9, 2025 virtual investor conference appearances announced.
-
Planned attendance at three major September 2025 healthcare conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and host one-on-one meetings at Sidoti’s Year-End Virtual Investor Conference, which is taking place from December 10-11, 2025.
Details of the presentation can be found below.
Presenter: Mark Erlander, PhD (CEO)
Date: 12/11/2025
Time: 4:00 PM ET
Interested parties can register for and access the live webcast for the conferences by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com
Investor Contact:
Candice Masse
Astr Partners
candice.masse@astrpartners.com
Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.